The specific price of anlotinib is affected by factors such as drug specifications, regions, and medical insurance policies. Currently, no pricing information is provided in the package insert, and it is necessary to consult formal medical institutions or pharmacies. This drug is a prescription medicine and must be used strictly in accordance with the doctor’s advice; it shall not be purchased or the dosage adjusted without authorization.
Anlotinib is mainly indicated for the treatment of specific types of advanced cancers, such as non-small cell lung cancer and soft tissue sarcoma. Its use must be evaluated by a doctor after a clear diagnosis. The standard dosage is 12 mg per dose, once daily, with continuous administration for 2 weeks followed by a 1-week drug holiday. Adverse reactions such as hypertension, hand-foot syndrome, and bleeding may occur during medication. It is necessary to monitor blood pressure, coagulation function and other indicators regularly, and adjust the dosage or discontinue the drug according to the doctor’s recommendations.
Precautions
1. Contraindicated Populations
Patients with hypersensitivity to any component of the drug, those with central squamous cell lung cancer, severe hepatic or renal insufficiency, as well as pregnant and lactating women are prohibited from using this drug.
Patients with bleeding risks (e.g., a history of hemoptysis or gastrointestinal bleeding) or coagulation dysfunction should use this drug with caution.
2. Adverse Reaction Management
In case of grade ≥2 bleeding events (e.g., hemoptysis, hematochezia), the drug should be suspended immediately and medical advice should be sought; permanent drug withdrawal is required for grade ≥3 bleeding or hypertension.
Hand-foot syndrome can be relieved by skin care and topical medication; dosage adjustment is needed if the condition is severe.
3. Medication in Special Populations
No dosage adjustment is required for elderly patients, but close monitoring of adverse reactions is necessary.
Strict contraception should be adopted during the medication period. If the drug is used during pregnancy, treatment should be stopped immediately and medical attention should be obtained.
Medical Consultation Guidelines
Anlotinib must be used under the guidance of an oncologist. Relevant examinations (e.g., genetic testing, pathological staging) should be completed before treatment. During medication, if symptoms such as chest pain, dyspnea, severe diarrhea, or headache occur, the doctor should be contacted promptly. This drug may interact with other metabolic enzyme inhibitors or inducers (e.g., rifampicin, ciprofloxacin), so patients must inform the doctor of all other drugs they are taking.
